Report of Foreign Issuer (6-k)
17 Juni 2019 - 3:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June, 2019
Commission File Number:
001-38475
ASLAN PHARMACEUTICALS LIMITED
(Translation of registrants name into English)
ASLAN Pharmaceuticals Limited
83 Clemenceau Avenue
#12-03
UE Square
Singapore 239920
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F:
Form
20-F
☒ Form
40-F
☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Amendment to License Agreement
As previously disclosed, on May 12, 2014, we entered into a license agreement with CSL Limited (CSL), pursuant to which we obtained an
exclusive, worldwide license to certain patents,
know-how
and other intellectual property owned or controlled by CSL related to CSLs anti-IL13 receptor monoclonal antibody, CSL334, which we refer to as
ASLAN004, and antigen binding fragments thereof.
On May 31, 2019, we amended and restated the license agreement with CSL, which primarily expanded
the scope of the license to allow us to develop, manufacture for clinical trials and commercialize ASLAN004 for the treatment, diagnosis or prevention of diseases or conditions in humans (the Amendment). The development under such
Amendment is currently focused on the treatment of respiratory and inflammatory conditions, and in particular, atopic dermatitis.
The foregoing
description of the Amendment is not a complete description of all terms and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Exhibits
*
|
Certain portions of this exhibit (indicated by [***]) have been omitted as the Registrant has
determined (i) the omitted information is not material and (ii) the omitted information would likely cause harm to the Registrant if publicly disclosed.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ASLAN PHARMACEUTICALS LIMITED
|
|
|
|
|
Date: June 17, 2019
|
|
|
|
By:
|
|
/s/ Kiran Kumar Asarpota
|
|
|
|
|
|
|
Name: Kiran Kumar Asarpota
|
|
|
|
|
|
|
Title: VP Finance
|
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024